Welcome to our dedicated page for Roche Hldg news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Hldg stock.
Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
Genentech (OTCQX:RHHBY) received FDA priority review for a supplemental BLA for Enspryng (satralizumab) to treat thyroid eye disease (TED). A decision is expected by October 15, 2026.
Phase III SatraGO data showed improvements in proptosis, clinical activity score, and diplopia, with no new safety signals and at-home subcutaneous dosing potential.
Roche (OTCQX:RHHBY) received FDA Priority Review for a supplemental Biologics License Application for Enspryng (satralizumab) to treat thyroid eye disease (TED). The application is supported by global phase III SatraGO-1 and SatraGO-2 data, with an FDA decision expected by 15 October 2026.
Enspryng is a subcutaneous therapy designed for convenient at-home use, showing improvements in proptosis, clinical activity score, and double vision, with no new safety signals reported.
Roche (OTCQX:RHHBY) launched AXELIOS 1, a next-generation sequencing platform based on SBX technology that combines high accuracy, speed, flexibility, scalability and cost efficiency.
The system enables end-to-end, same-day whole-genome sequencing in research, supports projects from small studies to massive cohorts, and debuts with real-world validation and collaborations with Hartwig Medical Foundation, Broad Clinical Labs, 10x Genomics and Google DeepVariant/XOOS tools in a USD 7.3 billion sequencing market.
Roche (OTCQX:RHHBY) reported that the FDA has accepted a supplemental Biologics License Application for subcutaneous Lunsumio VELO plus Polivy in adults with relapsed or refractory large B-cell lymphoma after ≥1 prior therapy, with a decision expected by 9 February 2027.
Phase III SUNMO data showed a 59% reduction in risk of disease progression or death versus R-GemOx (HR 0.41), and median PFS of 11.5 months versus 3.8 months. Safety was consistent with known profiles, with low cytokine release syndrome incidence.
Roche (OTCQX:RHHBY) received FDA approval for the VENTANA PTEN (SP218) RxDx Assay, the first IHC companion diagnostic to assess PTEN protein loss in prostate adenocarcinoma.
The test helps identify patients with PTEN-deficient metastatic mAPMN/S prostate cancer who may be eligible for combination treatment with TRUQAP (capivasertib), supporting more personalised therapy.
Genentech (OTCQX:RHHBY) reported that the FDA accepted its supplemental Biologics License Application and granted Priority Review for adjuvant Tecentriq and Tecentriq Hybreza plus chemotherapy in stage III dMMR/MSI-H colon cancer.
The review is based on Phase III ATOMIC data showing a 50% reduction in recurrence or death risk and 36‑month disease-free survival of 86% versus 76% with chemotherapy alone. The FDA decision is expected by October 9, 2026.
Roche (OTCQX:RHHBY) received FDA Priority Review for a supplemental Biologics License Application for adjuvant Tecentriq and Tecentriq Hybreza plus chemotherapy in stage III dMMR/MSI-H colon cancer after surgery.
The filing is supported by phase III ATOMIC data showing a 50% reduction in recurrence or death risk and 36‑month disease‑free survival of 86% vs 76% with chemotherapy alone. The FDA decision is expected by 9 October 2026, and Roche is pursuing additional global filings.
Roche (OTCQX:RHHBY) received European Union IVDR approval for label expansions of its VENTANA MMR RxDx Panel companion diagnostic.
The test now covers five cancer types and six indications, helping identify mismatch repair status to guide use of KEYTRUDA, IMFINZI, IMFINZI+LYNPARZA and JEMPERLI in eligible patients.
Roche (OTCQX:RHHBY) entered an exclusive global licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialise bexobrutideg (NX-5948), an oral BTK degrader for B-cell malignancies, immunology and neurology.
Bexobrutideg is planned to enter Phase 3 CLL trials in summer 2026. Nurix receives $700 million upfront and may earn up to $2.3 billion in total deal value, including milestones. Development costs are shared 60% Roche / 40% Nurix, with 50/50 U.S. profit and loss sharing and ex-U.S. royalties for Nurix in the low- to high-teens.
The transaction is subject to customary conditions, including Hart-Scott-Rodino clearance, and is expected to close in the third quarter of 2026.
Roche (OTCQX:RHHBY) has developed a Research Use Only PCR test to detect the rare Ebola Bundibugyo virus. Created within six days of the genome sequence release via TIB MOLBIOL, it runs on LightCycler and cobas z 480 platforms.
The assay supports outbreak response in Central and East Africa, where WHO declared a Public Health Emergency on 17 May 2026. TIB MOLBIOL leveraged a rapid-response library of 15,000 test pre-designs and 3,000 positive control materials, and works with public health labs to expand frontline testing and surveillance.